The effect of midazolam on the improvement of hysteria symptoms

Comparison of the effect of midazolam drug with placebo in improving the symptoms of hysterical patients referred to the emergency department

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220516054869N4

Enrollment

Registered

2023-01-19

Start date

2022-12-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysterical patients. Dissociative and conversion disorders

Interventions

Intervention 1: Intervention group: EXIR pharmaceutical company's midazolam ampoule is 2 mg in a volume of 2 cc, which will be infused intravenously for 2 minutes. Intervention 2: Control group: 2 cc

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: All confirmed hysterical patients by emergency medicine specialists in the emergency room Informed consent of the patient or her / his companion

Exclusion criteria

Exclusion criteria: Age less than 18 years and more than 60 years pregnacy History of liver disease Allergy to study drugs

Design outcomes

Primary

Measure	Time frame
Agitation. Timepoint: 0, 30, 60 minutes. Method of measurement: The presence or absence of symptoms based on clinical diagnosis by an emergency physician.;Failure to communicate with others. Timepoint: 0, 30, 60 minutes. Method of measurement: The presence or absence of symptoms based on clinical diagnosis by an emergency physician.;To cry. Timepoint: 0, 30, 60 minutes. Method of measurement: The presence or absence of symptoms based on clinical diagnosis by an emergency physician.;Dysphonia. Timepoint: 0, 30, 60 minutes. Method of measurement: The presence or absence of symptoms based on clinical diagnosis by an emergency physician.	—

Measure

Time frame

Agitation. Timepoint: 0, 30, 60 minutes. Method of measurement: The presence or absence of symptoms based on clinical diagnosis by an emergency physician.;Failure to communicate with others. Timepoint: 0, 30, 60 minutes. Method of measurement: The presence or absence of symptoms based on clinical diagnosis by an emergency physician.;To cry. Timepoint: 0, 30, 60 minutes. Method of measurement: The presence or absence of symptoms based on clinical diagnosis by an emergency physician.;Dysphonia. Timepoint: 0, 30, 60 minutes. Method of measurement: The presence or absence of symptoms based on clinical diagnosis by an emergency physician.

—

Secondary

Measure	Time frame
Weaknes. Timepoint: 60 minutes after the intervention. Method of measurement: According to the history of the patient.;Drowsiness. Timepoint: 0, 30, 60 minutes. Method of measurement: The presence or absence of symptoms based on clinical diagnosis by an emergency physician.;Apnea. Timepoint: 30,6o minutes. Method of measurement: The presence or absence of symptoms based on clinical diagnosis by an emergency physician.;Decreased breathing rate. Timepoint: 0,30,60 minutes. Method of measurement: The presence of a normal breathing rate of less than 12 per minute by observing the movements of the chest by an emergency physician.	—

Measure

Time frame

Weaknes. Timepoint: 60 minutes after the intervention. Method of measurement: According to the history of the patient.;Drowsiness. Timepoint: 0, 30, 60 minutes. Method of measurement: The presence or absence of symptoms based on clinical diagnosis by an emergency physician.;Apnea. Timepoint: 30,6o minutes. Method of measurement: The presence or absence of symptoms based on clinical diagnosis by an emergency physician.;Decreased breathing rate. Timepoint: 0,30,60 minutes. Method of measurement: The presence of a normal breathing rate of less than 12 per minute by observing the movements of the chest by an emergency physician.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Abdolrazaghnejad

Zahedan University of Medical Sciences

ali.abdorazzagh@gamil.com+98 54 3323 2890

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026